Equities analysts forecast that Viking Therapeutics Inc (NASDAQ:VKTX) will post earnings per share (EPS) of ($0.10) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Viking Therapeutics’ earnings. The lowest EPS estimate is ($0.12) and the highest is ($0.09). Viking Therapeutics reported earnings per share of ($0.14) in the same quarter last year, which suggests a positive year-over-year growth rate of 28.6%. The company is expected to issue its next earnings results on Wednesday, March 6th.
On average, analysts expect that Viking Therapeutics will report full-year earnings of ($0.43) per share for the current financial year, with EPS estimates ranging from ($0.45) to ($0.40). For the next year, analysts anticipate that the firm will post earnings of ($0.46) per share, with EPS estimates ranging from ($0.55) to ($0.34). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Viking Therapeutics.
Several research firms have recently weighed in on VKTX. Maxim Group reiterated a “buy” rating and set a $28.00 price objective on shares of Viking Therapeutics in a research report on Thursday, November 8th. Raymond James upgraded shares of Viking Therapeutics from an “outperform” rating to a “strong-buy” rating and set a $43.00 price objective for the company in a report on Monday, November 19th. They noted that the move was a valuation call. B. Riley initiated coverage on shares of Viking Therapeutics in a research report on Tuesday, December 11th. They set a “buy” rating and a $16.00 price target on the stock. BidaskClub raised shares of Viking Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Viking Therapeutics in a research note on Thursday, November 8th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $26.29.
Shares of NASDAQ VKTX traded down $0.24 during trading hours on Friday, hitting $8.73. 83,716 shares of the stock were exchanged, compared to its average volume of 2,741,031. The firm has a market capitalization of $570.25 million, a price-to-earnings ratio of -11.06 and a beta of 2.76. Viking Therapeutics has a 1-year low of $3.69 and a 1-year high of $24.00.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
See Also: Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.